Idexx Laboratories price target lowered to $548 from $559 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Idexx Laboratories (IDXX) to $548 from $559 and keeps an Overweight rating on the shares. While policy will be “front and center” with varying degrees of exposure, or lack there of, across the Healthcare Services and Technology space, the focus will also be on indications of underlying utilization trends across MCOs, distributors, providers, labs, animal and dental into Q1, the analyst tells investors in a preview for the group.